Table of Contents

company-logo

OncoTherapy Science, Inc. researches and develops anti-cancer medicines and therapies in Japan. Its clinical development product pipeline includes small-molecule drugs, such as OTS167, a maternal embryonic leucine zipper kinase inhibitor that is in Phase I/II clinical trials for the treatment of acute myeloid leukemia, as well as in Phase I clinical trials for the treatment of breast cancer; and OTS964, a T-LAK cell-originated protein kinase inhibitor for the treatment of various cancer diseases. The company's clinical development product pipeline also comprise cancer- specific peptide vaccines, including S-588410, which is in Phase III clinical trials for the treatment esophageal cancer, as well as in Phase II clinical trials for the treatment of bladder cancer; S-488210 that is in Phase I/II clinical trials for the treatment of head and neck cancer; and S-588210, which is in Phase I clinical trials for the treatment of solid tumor. In addition, it is developing antibody drugs consisting of OTSA101, which is in Phase I clinical trials for synovial sarcoma; and KHK6640, an anti-amyloid beta peptide antibody that is Phase I clinical trials for Alzheimer's disease. Further, the company provides contract analysis services. OncoTherapy Science, Inc. was founded in 2001 and is headquartered in Kawasaki, Japan.

OncoTherapy Science Dividend Announcement

• OncoTherapy Science does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on OncoTherapy Science dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

OncoTherapy Science Dividend History

OncoTherapy Science Dividend Yield

OncoTherapy Science current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing OncoTherapy Science stock? Use our calculator to estimate your expected dividend yield:

OncoTherapy Science Financial Ratios

P/E ratio-6.07
PEG ratio0.21
P/B ratio10.07
ROE-178.77%
Payout ratio0.00%
Current ratio2.99
Quick ratio2.67
Cash Ratio1.99

OncoTherapy Science Dividend FAQ

Does OncoTherapy Science stock pay dividends?
OncoTherapy Science does not currently pay dividends to its shareholders.
Has OncoTherapy Science ever paid a dividend?
No, OncoTherapy Science has no a history of paying dividends to its shareholders. OncoTherapy Science is not known for its dividend payments.
Why doesn't OncoTherapy Science pay dividends?
There are several potential reasons why OncoTherapy Science would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will OncoTherapy Science ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While OncoTherapy Science has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is OncoTherapy Science a dividend aristocrat?
OncoTherapy Science is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is OncoTherapy Science a dividend king?
OncoTherapy Science is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is OncoTherapy Science a dividend stock?
No, OncoTherapy Science is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy OncoTherapy Science stocks?
To buy OncoTherapy Science you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy OncoTherapy Science stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.